Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

SELL
$9.99 - $18.71 $229,460 - $429,749
-22,969 Reduced 29.96%
53,694 $995,000
Q2 2023

Aug 09, 2023

BUY
$9.17 - $19.29 $147,627 - $310,549
16,099 Added 26.58%
76,663 $847,000
Q1 2023

May 12, 2023

BUY
$12.53 - $21.71 $555,505 - $962,491
44,334 Added 273.16%
60,564 $813,000
Q4 2022

Feb 09, 2023

SELL
$11.61 - $16.11 $788,446 - $1.09 Million
-67,911 Reduced 80.71%
16,230 $200,000
Q3 2022

Nov 09, 2022

BUY
$12.21 - $19.7 $1.03 Million - $1.66 Million
84,141 New
84,141 $1.17 Million
Q2 2022

Aug 11, 2022

SELL
$11.23 - $19.59 $625,511 - $1.09 Million
-55,700 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$13.37 - $17.79 $544,653 - $724,711
40,737 Added 272.25%
55,700 $906,000
Q4 2021

Feb 11, 2022

BUY
$14.28 - $19.53 $213,671 - $292,227
14,963 New
14,963 $244,000
Q1 2020

May 13, 2020

SELL
$48.35 - $118.68 $4,835 - $11,868
-100 Closed
0 $0
Q4 2019

Feb 10, 2020

SELL
$57.36 - $124.1 $3.06 Million - $6.61 Million
-53,300 Reduced 99.81%
100 $12,000
Q3 2019

Nov 12, 2019

BUY
$58.69 - $80.46 $3.13 Million - $4.3 Million
53,400 New
53,400 $3.54 Million
Q3 2018

Nov 08, 2018

SELL
$88.49 - $127.55 $1.13 Million - $1.63 Million
-12,812 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$60.0 - $85.67 $697,920 - $996,513
-11,632 Reduced 47.59%
12,812 $1.08 Million
Q1 2018

May 11, 2018

BUY
$52.72 - $67.25 $221,054 - $281,979
4,193 Added 20.71%
24,444 $1.5 Million
Q4 2017

Feb 09, 2018

BUY
$58.2 - $72.76 $289,428 - $361,835
4,973 Added 32.55%
20,251 $1.18 Million
Q3 2017

Nov 15, 2017

BUY
$57.01 - $118.75 $631,328 - $1.32 Million
11,074 Added 263.42%
15,278 $887,000
Q2 2017

Aug 14, 2017

BUY
N/A
4,204
4,204 $509,000

Others Institutions Holding ICPT

About INTERCEPT PHARMACEUTICALS, INC.


  • Ticker ICPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,127,400
  • Description
  • Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...
More about ICPT
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.